284 related articles for article (PubMed ID: 29130794)
1. Allergen immunotherapy for birch-apple syndrome: what do we know?
Incorvaia C; Ridolo E; Mauro M; Russello M; Pastorello E
Immunotherapy; 2017 Nov; 9(15):1271-1278. PubMed ID: 29130794
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
[TBL] [Abstract][Full Text] [Related]
3. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
[TBL] [Abstract][Full Text] [Related]
4. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1.
Kinaciyan T; Jahn-Schmid B; Radakovics A; Zwölfer B; Schreiber C; Francis JN; Ebner C; Bohle B
J Allergy Clin Immunol; 2007 Apr; 119(4):937-43. PubMed ID: 17204315
[TBL] [Abstract][Full Text] [Related]
5. Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice.
Utsch L; Logiantara A; Wallner M; Hofer H; van Ree R; van Rijt LS
Clin Exp Allergy; 2016 Nov; 46(11):1474-1483. PubMed ID: 27376790
[TBL] [Abstract][Full Text] [Related]
6. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy.
Kinaciyan T; Nagl B; Faustmann S; Kopp S; Wolkersdorfer M; Bohle B
Allergy; 2016 Feb; 71(2):272-4. PubMed ID: 26443126
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy.
van der Valk JPM; Nagl B; van Wljk RG; Bohle B; de Jong NW
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32085633
[TBL] [Abstract][Full Text] [Related]
9. High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China.
Hao GD; Zheng YW; Wang ZX; Kong XA; Song ZJ; Lai XX; Spangfort MD
J Zhejiang Univ Sci B; 2016 May; 17(5):399-404. PubMed ID: 27143268
[TBL] [Abstract][Full Text] [Related]
10. Allergy to apple cultivars among patients with birch pollinosis and oral allergy syndrome.
Wagner A; Szwed A; Buczyłko K; Wagner W
Ann Allergy Asthma Immunol; 2016 Oct; 117(4):399-404. PubMed ID: 27593099
[TBL] [Abstract][Full Text] [Related]
11. Birch-apple syndrome treated with birch pollen immunotherapy.
Mauro M; Russello M; Incorvaia C; Gazzola G; Frati F; Moingeon P; Passalacqua G
Int Arch Allergy Immunol; 2011; 156(4):416-22. PubMed ID: 21832831
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of component-resolved diagnosis in Japanese birch-allergic patients with a convincing history of apple or peach allergy.
Shirasaki H; Yamamoto T; Abe S; Kanaizumi E; Kikuchi M; Himi T
Auris Nasus Larynx; 2017 Aug; 44(4):442-446. PubMed ID: 27816237
[TBL] [Abstract][Full Text] [Related]
13. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
14. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
15. Allergen-specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy.
Nothegger B; Reider N; Covaciu CE; Cova V; Ahammer L; Eidelpes R; Unterhauser J; Platzgummer S; Tollinger M; Letschka T; Eisendle K
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1286-1292. PubMed ID: 31953891
[TBL] [Abstract][Full Text] [Related]
16. Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen.
Son DY; Scheurer S; Hoffmann A; Haustein D; Vieths S
Eur J Nutr; 1999 Aug; 38(4):201-15. PubMed ID: 10502033
[TBL] [Abstract][Full Text] [Related]
17. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
18. Sensitization profiles in birch pollen-allergic patients with and without oral allergy syndrome to apple: lessons from multiplexed component-resolved allergy diagnosis.
Ebo DG; Bridts CH; Verweij MM; De Knop KJ; Hagendorens MM; De Clerck LS; Stevens WJ
Clin Exp Allergy; 2010 Feb; 40(2):339-47. PubMed ID: 19709127
[TBL] [Abstract][Full Text] [Related]
19. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
Cudowska B; Kaczmarski M; Restani P
Rocz Akad Med Bialymst; 2005; 50():268-73. PubMed ID: 16358981
[TBL] [Abstract][Full Text] [Related]
20. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
Sánchez Acosta G; Kinaciyan T; Kitzmüller C; Möbs C; Pfützner W; Bohle B
J Allergy Clin Immunol; 2020 Oct; 146(4):894-900.e2. PubMed ID: 32259540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
